About Haley Chartres

This author has yet to write their bio.
Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 31 entries.

Entries by Haley Chartres

Novartis’ Sandoz splurges on a trio of GSK antibiotics, doubling down with a $500M bet on a field struggling to combat resistant microbes

Article extract | “Novartis’ acquisition represents a double-down on an antibiotics field facing an existential crisis from resistant “super bugs” that have sent most major drugmakers running for the hills — including Novartis, which dumped its antibiotic R&D program in 2018. But adding ever-greater volume to their generic antibiotics portfolio could offer Novartis some bottom-line […]

ScoPo’s powerplays: Jazz Pharma’s $9.4b deal highlights pot plays

‘A huge acquisition in the international medical cannabis sector is set to give tailwinds to several ASX-listed marijuana companies, Scott Power says. Ireland-based Jazz Pharmaceuticals (NASDAQ:JAZZ) this week agreed to buy cannabinoid drugmaker GW Pharmaceuticals (NASDAQ:GWPH) for $US7.2 billion ($9.4 billion) – a 50 per cent premium to GW’s closing price on Tuesday.’ Click through to read the full article […]

Botanix soars after pot-up-nose study success

‘Botanix Pharmaceuticals (ASX:BOT) shares have soared after a small clinical trial backed the feasibility of putting synthetic cannabis up the nose of surgical patients to prevent infections. While cannabis is of course mostly known for its psychoactive properties, a number of companies trying to unlock its therapeutic benefit and Botanix’s research has shown that cannabidiol (CBD) is […]

World first | Human clinical study shows synthetic CBD formula eradicates Staphylococcus Aureus

Philadelphia PA and Sydney Australia, 3 February 2021: Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals Limited has today published positive data from a world first human clinical study, examining the safety, tolerability and efficacy of its BTX 1801 antimicrobial product for the eradication of Staphylococcus Aureus (Staph). Staph, also called golden staph, is a common […]

CBD oil kills gonorrhoea bacteria, potential for ‘much-needed new class of antibiotics’

Groundbreaking new research has found synthetic cannabidiol can kill bacteria associated with gonorrhoea, meningitis and legionnaires disease. The research, published in a peer-reviewed journal article in Communications Biology on Wednesday, explores antimicrobial activity of CBD and the potential to advance CBD analogs as a “much-needed new class of antibiotics”. It found the psychoactive component of […]

Qld researchers on how cannabis could be used to fight superbug

Queensland researchers are studying a component of medicinal cannabis for its potential as a new antibiotic, capable of killing superbugs. The big hope for scientists at the University of Queensland’s Institute for Molecular Bioscience is that synthetic cannabidiol, or CBD, the main non-psychoactive component of cannabis, could be developed into the first new class of […]

Journal article | “The antimicrobial potential of cannabidiol”

An important research project testing the targeted capabilities of our antimicrobial platform, conducted in collaboration with The University of Queensland, has been published in Communications Biology ­– a leading peer-reviewed journal by Nature Research. The research article titled “The antimicrobial potential of cannabidiol” reveals the unique mechanism through which synthetic cannabidiol can kill the bacteria […]

Oxford research tackles threat of antibiotic resistance

Oxford University is opening a new research institute dedicated to tackling resistance to antibiotics. The university says this is one of the the biggest rising threats to global health, already causing 1.5 million deaths per year worldwide. The institute will be funded by £100m donated by the Ineos chemical company. Click through to read the […]